CODX — Co-Diagnostics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.94m
- -$6.95m
- $0.62m
Annual cashflow statement for Co-Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 36.7 | -14.2 | -35.3 | -37.6 | -46.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 6.05 | 18 | 8.8 | 4.35 | 19.8 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.9 | 6.37 | 5.64 | 2.75 | -3.17 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 41.1 | 6.57 | -22.1 | -29.2 | -29.1 |
| Capital Expenditures | -0.669 | -1.43 | -1.37 | -0.748 | -0.7 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 4.77 | -56.7 | 16.8 | 17.8 | 27 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 4.1 | -58.2 | 15.4 | 17.1 | 26.3 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.45 | -14 | -1.36 | 0.104 | 11.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 45.6 | -65.6 | -8.06 | -12 | 8.95 |